3月26日,云顶新耀(01952.HK)披露2025年全年业绩报告。报告期内,公司实现总收入17.07亿元,同比增长142%;非国际财务报告准则(Non-IFRS)下,公司首次实现年度盈利,由上年同期的亏损5.38亿元转为盈利1.87亿元。 《每日经济新闻》记者注意到,云顶新耀业绩改善主要得益于其IgA肾病药物耐赋康(布地奈德肠溶胶囊)医保执行下的快速放量。2025年度,耐赋康销售收入突破14...
Source Link3月26日,云顶新耀(01952.HK)披露2025年全年业绩报告。报告期内,公司实现总收入17.07亿元,同比增长142%;非国际财务报告准则(Non-IFRS)下,公司首次实现年度盈利,由上年同期的亏损5.38亿元转为盈利1.87亿元。 《每日经济新闻》记者注意到,云顶新耀业绩改善主要得益于其IgA肾病药物耐赋康(布地奈德肠溶胶囊)医保执行下的快速放量。2025年度,耐赋康销售收入突破14...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.